The European Menopause Survey 2005: Women's perceptions on the menopause and postmenopausal hormone therapy

Gynecological Endocrinology

Volumn 22, Issue 7, 2006, Pages 369-375

  Genazzani, Andrea ^a,e   Schneider, Hermann ^b   Panay, Nick ^c   Nijland, Esme ^d  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c QUEEN CHARLOTTE S AND CHELSEA HOSPITAL   (United Kingdom)

^d NV ORGANON   (Netherlands)

^e UNIVERSITY OF PISA   (Italy)

Author keywords

Breast cancer; Compliance; Menopause; Survey

Indexed keywords

HORMONE; NATURAL PRODUCT;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEALTH SURVEY; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RISK ASSESSMENT; TREATMENT OUTCOME;

BREAST DISEASES; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; ESTROGEN REPLACEMENT THERAPY; EUROPE; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; RISK FACTORS;

EID: 33746858931     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590600842463     Document Type: Article

References (34)

1. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998;280:605-613.
2. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, et al., for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy - Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). J Am Med Asoc 2002;288:49-57.
3. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, et al., for the HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy - Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). J Am Med Assoc 2002;288:58-66.
4. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002;288:321-333.
5. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. J Am Med Assoc 2002;288:366-368.
6. North American Menopause Society. Amended report from the NAMS Advisory Panel on postmenopausal hormone therapy. Menopause 2003;10:6-12.
7. Executive Committee of the International Menopause Society. Guidelines for the hormone treatment of women in the menopausal transition and beyond. Climacteric 2004;7:8-11.
8. Skouby SO. Climacteric medicine: European Menopause and Andropause Society (EMAS) statements on postmenopausal hormone therapy. Maturitas 2004;48:19-25.
9. McDonough PG. The randomized world is not without its imperfections: reflections on the Women's Health Initiative Study. Fertil Steril 2002;78:951-956.
10. Barlow DH. Time to reflect on the Women's Health Initiative (WHI) Study. Hum Reprod 2003;18:1-3.
11. Lawton B, Rose S, McLeod D, Dowell A. Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users. Br Med J 2003;327:845-846.
12. Bestul MB, McCollum M, Hansen LB, Saseen JJ. Impact of the Women's Health Initiative trial results on hormone replacement therapy. Pharmacotherapy 2004;24:495-499.
13. Hoffmann M, Hammar M, Kjellgren KI, Lindh-Åstrand L, Brynhildsen J. Changes in women's attitudes towards and use of hormone therapy after HERS and WHI. Maturitas 2005;52:11-17.
14. Breslau ES, Davis WW, Doner L, Eisner EJ, Goodman NR, Meissner HI, Rimer BK, Rossouw JE. The hormone therapy dilemma: women respond. J Am Med Womens Assoc 2003;58:33-43.
15. Strothmann A, Schneider HPG. Hormone therapy: the European women's perspective. Climacteric 2003;6:337-346.
16. Blümel JE, Castelo-Branco C, Chedraui PA, Binfa L, Dowlani B, Gomez MS, Sarra S. Patients' and clinicians' attitudes after the Women's Health Initiative. Menopause 2004;11:57-61.
17. Barber CA, Margolis K, Luepker RV, Arnett DK. The impact of the Women's Health Initiative on discontinuation of postmenopausal hormone therapy: the Minnesota Heart Survey (2000-2002). J Womens Health 2004;13:975-985.
18. Ettinger B, Grady D, Tosteson ANA, Pressman A, Macer JL. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225-1232.
19. Moen MH, Nilsen S-T, Iversen O-E. A significant change in Norwegian gynecologist's attitude to hormone therapy is observed after the results of the Women's Health Initiative study. Acta Obstet Gynecol Scand 2005;84:92-93.
20. Newton KM, Buist DSM, Miglioretti DL, Beverly K, Hartsfield CL, Chan KA, Andrade SE, Wei F, Connelly MT, Kessler L. The impact of comorbidities on hormone use. J Gen Intern Med 2005;20:350-356.
21. Hillman JJ, Zuckerman IH, Lee E. The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program. J Womens Health 2004;13:986-992.
22. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 2004;140:184-188.
23. Wysowsky DK, Governale LA. Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiol Drug Saf 2005;14:171-176.
24. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy - annual trends and response to recent evidence. J Am Med Assoc 2004;291:47-53.
25. Beral V, for the Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
26. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. J Am Med Assoc 2004;291:1701-1712.
27. NAMS. Position Statement. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004;11:11-33.
28. Executive Committee of the International Menopause Society. Guidelines for the hormone treatment of women in the menopausal transition and beyond. Climacteric 2004;7:8-11.
29. Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M, Hilton E, Bailey S, Barrett N, Briers P, et al. Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect. Breast Cancer Res 2006;8:R8.
30. Hulka BS, Moorman PG. Breast cancer: hormones and other risk factors. Maturitas 2001;38:103-116.
31. SOGC Clinical Practice Guidelines. Use of hormonal replacement therapy after treatment of breast cancer. Int J Gynecol Obstet 2005;88:216-221.
32. McPherson K, Steel CM, Dixon JM. ABC of Breast diseases. Breast cancer - epidemiology, risk factors, and genetics. Br Med J 2000;321:624-628.
33. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-365.
34. Klaiber EL, Vogel W, Rako S. A critique of the Women's Health Initiative hormone therapy study. Fertil Steril 2005;84:1589-1601.